Lung Neoplasms
Conditions
Brief summary
Purpose of the study: To observe the efficacy and safety of Anlotinib Hydrochloric Therapy in Patients with advanced Lung cancer in real world. Subjects of the study: advanced Lung cancer. Methods of the study: This is a real world, prospective, Non-Interventional, Follow-up registration study. Patients will get Anlotinib according to their condition and willingness. Anlotinib will give orally, once daily on days 1-14 of a 21-day cycle. After the procedure, regular follow up after every cycle. End point: Primary end point: progression-free survival (PFS). Secondary end points: overall survival (OS), disease control rate (DCR), overall response rate (ORR).
Interventions
DRUGAnlotinib Hydrochloride
Anlotinib will give orally, once daily on days 1-14 of a 21-day cycle. Dose reduction is allowed.
Sponsors
Cttq
First People's Hospital of Hangzhou
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients ≥18 years of age, man or woman, who had to provide written informed consent prior to enrollment. 2. Patients who had to have histologically and/or cytologically confirmed NSCLC that failed at least 2 kinds of systemic chemotherapy (third line or beyond), or who will obtain benefit from antiangiogenic therapy after investigator's assessment. 3. Eastern Cooperative Oncology Group performance status of 0-2.
Exclusion criteria
1. Contraindication of anlotinib. 2. Pregnant or lactating women. 3. Other patients who can't enroll after investigator's assessment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PFS | 1 year | progression-free survival |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| OS | 1 year | overall survival |
| ORR | 1 year | overall response rate |
| DCR | 1 year | disease control rate |
Countries
China
Contacts
Primary ContactXueqin Chen
Outcome results
None listed